1620 Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

1620 Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.2K	Sell	834 -143	-15%	-$3.38K	0.01%	415
2026 Q1	$22.1K	Hold	977	–	–	0.01%	386
2025 Q4	$25.3K	Hold	977	–	–	0.02%	370
2025 Q3	$25.2K	Hold	977	–	–	0.02%	363
2025 Q2	$23.4K	Sell	977 -15	-2%	-$378	0.02%	380
2025 Q1	$24.7K	Hold	992	–	–	0.02%	364
2024 Q4	$18.7K	Sell	992 -35	-3%	-$615	0.01%	397
2024 Q3	$15.5K	Buy	1,027 +439	+75%	+$7.51K	0.01%	433
2024 Q2	$16.8K	Buy	+588	New	+$16.7K	0.01%	416

Other funds holding PCRX

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $77B AUM 50.57% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Milestone Asset Management Pittsburgh, Pennsylvania $635M AUM 22.1% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $6.82B AUM 30.02% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.6B AUM 29.42% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Adirondack Trust Company Saratoga Springs, New York $336M AUM 29.2% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return